The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus

Autor: Tamar Aprahamian, Chris Andry, Christophe Richez, Zachary Weitzner, Ian R. Rifkin, Rocco J. Richards, Pierre Duffau
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Apolipoprotein E
Mouse
Lupus nephritis
lcsh:Medicine
Cardiovascular
Eating
Mice
0302 clinical medicine
immune system diseases
Lupus Erythematosus
Systemic

skin and connective tissue diseases
lcsh:Science
0303 health sciences
Nephritis
Multidisciplinary
Systemic lupus erythematosus
Animal Models
3. Good health
Disease Progression
Medicine
medicine.symptom
Immunosuppressive Agents
Research Article
medicine.drug
Fas Ligand Protein
Clinical Research Design
Immunology
Inflammation
Systemic Lupus Erythematosus
Mycophenolic acid
Autoimmune Diseases
03 medical and health sciences
Apolipoproteins E
Model Organisms
Immune system
Rheumatology
medicine
Animals
Humans
Animal Models of Disease
Lymphatic Diseases
Biology
Autoantibodies
030304 developmental biology
030203 arthritis & rheumatology
Lupus Erythematosus
business.industry
Body Weight
lcsh:R
Immunity
Autoantibody
Mycophenolic Acid
Atherosclerosis
medicine.disease
Disease Models
Animal

Splenomegaly
Clinical Immunology
lcsh:Q
business
Zdroj: PLoS ONE, Vol 8, Iss 4, p e61042 (2013)
PLoS ONE
ISSN: 1932-6203
Popis: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is characterized by autoantibody production and inflammatory disease involving multiple organs. Premature atherosclerosis is a common complication of SLE and results in substantial morbidity and mortality from cardiovascular disease (CVD). The reasons for the premature atherosclerosis in SLE are incompletely understood, although chronic inflammation is thought to play an important role. There is currently no known preventative treatment of premature atherosclerosis in SLE. Mycophenolate mofetil (MMF) is an immunosuppressive agent that is commonly used for treatment of patients with SLE. In order to study the impact of this drug on murine lupus disease including premature atherosclerosis development, we treated gld.apoE(-/-) mice, a model of SLE and accelerated atherosclerosis, with MMF. We maintained seven-week old gld.apoE(-/-) mice on a high cholesterol Western diet with or without MMF. After 12 weeks on diet, mice receiving MMF showed decreased atherosclerotic lesion area compared to the control group. MMF treatment also improved the lupus phenotype, indicated by a significant decrease circulating autoantibody levels and ameliorating lupus nephritis associated with this model. This data suggests that the effects of MMF on the immune system may not only be beneficial for lupus, but also for inflammation driving lupus-associated atherosclerosis.
Databáze: OpenAIRE